Categories Other Industries

Biogen shares rally on success of experimental Alzheimer’s drug

Shares of biotech company Biogen (BIIB) rallied on Thursday during the after-hours trading after the company said it achieved positive results from final analysis of its Phase II trial of an Alzheimer’s drug. The advanced drug candidate, BAN2401, was developed in partnership with a Tokyo-based pharma company Eisai.

The drug companies stated that their experimental drug, BAN2401, had significantly reduced the growth of the neurodegenerative disease after 18 months of treatment, thereby passing the mid-stage trial. This recent success marks an important breakthrough for Biogen in this field.

The companies, however, did not offer an update on its Phase III trial plans. If Biogen and Eisai succeed with positive results in Phase 3, it will be a huge achievement, as many pharma companies that have spent billions into R&D to find a cure for Alzheimer’s Disease have met with little success. Despite being a common disease in the US, there are currently only five drugs that are approved by the FDA to treat Alzheimer’s.

Recently, Biogen agreed to spend $700 million to boost its stake in Samsung Bioepis. When both the companies entered into a partnership in 2012, Biogen had an ownership of 5.4%. Now Biogen has increased it to 49.9% stake. Samsung Bioepis has a gained a firm foothold in biosimilar market and currently has six late-stage candidates in its pipeline.

According to FiercePharma, the reason why Biogen upped its stake in Samsung Bioepis is because of the looming competitive threat on Biogen’s Multiple Sclerosis franchise that has been a growth driver for the company.

Most Popular

Tyson Foods (TSN) Q1 2023 Earnings: Key financials and quarterly highlights

Tyson Foods Inc. (NYSE: TSN) reported first quarter 2023 earnings results today. Sales rose 2.5% year-over-year to $13.2 billion. Net income attributable to Tyson was $316 million, or $0.88 per

After weak start to 2023, Apple (AAPL) sees some bright spots

Apple Inc. (NASDAQ: AAPL) this week reported its first revenue decline in more than three years, even as the high inflation continues to squeeze customers’ spending power. Sales of the

Earnings: Qualcomm (QCOM) Q1 profit falls on lower revenues

Chipmaker Qualcomm, Inc. (NASDAQ: QCOM) has reported lower earnings and revenues for the first quarter of 2023. The company also provided guidance for the second quarter of 2023. At $9.5

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top